



## **PRESS RELEASE**

### **Crucell and DSM Announce PER.C6<sup>®</sup> Licensing Agreement with JCR Pharmaceuticals for Protein Production**

**Leiden/Sittard, The Netherlands, March 10, 2005** - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6<sup>®</sup> research license agreement with leading Japanese pharmaceutical company JCR Pharmaceuticals Co., Ltd. This license agreement allows JCR to use the PER.C6<sup>®</sup> cell line for production of certain recombinant therapeutic proteins.

Under the terms of the agreement, JCR will make a research license payment and annual maintenance fees. Further financial details were not disclosed.

#### **About Crucell**

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with sanofi aventis for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6<sup>®</sup> technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6<sup>®</sup> technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit [www.crucell.com](http://www.crucell.com).

#### **About DSM Biologics**

DSM Biologics, a business unit of the DSM Pharmaceutical Products business group, is one of the world's leading contract manufacturers of biopharmaceutical products, the latest generation of drugs, mainly on the basis of native molecules and produced with the help of cell cultures. The company is renowned for its experience in the use of a broad range of cell culture systems (microbial and mammalian) and its expertise in the field of purification techniques. Established in 1986, DSM Biologics currently employs about 450 people, who are based at the company's two sites, one in Groningen, the Netherlands (ca. 1,000 liters fermentor capacity and 6,000 m<sup>2</sup>) and one in Montreal, Quebec, Canada (ca. 6,500 liters fermentor capacity and presently 10,000 m<sup>2</sup>). DSM Biologics is a joint venture of DSM and Société générale de financement du Québec (SGF), an industrial and financial holding company, which carries out economic development projects, especially in the industrial sector, in cooperation with partners and in accordance with accepted requirements for profitability that comply with the economic development policy of the Government of Québec. For more information, please visit [www.dsmbiologics.com/](http://www.dsmbiologics.com/).

DSM Biologics is represented by Asahi Glass Co., Ltd. in Japan for the licensing of the PER.C6<sup>®</sup> technology.

The logo for DSM, consisting of the letters "DSM" in a bold, blue, sans-serif font.

## **About JCR**

JCR Pharmaceuticals Co., Ltd., is a biopharmaceutical company founded in 1975 to research, develop and manufacture human-derived bioactive substances. While JCR engages in the manufacture of enzymes and hormones, its recent activities include the research and development of cell therapies and orphan drugs. JCR's core product is recombinant human growth hormone, which is manufactured and sold in Japan. JCR is listed on Second Section of Osaka Stock Exchange (code 4552). For more information, please visit [www.jcrpharm.co.jp](http://www.jcrpharm.co.jp).

*This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on February 27, 2004, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States.*

## **For further information please contact:**

### **Crucell N.V.**

Leonard Kruimer  
Chief Financial Officer  
Tel. +31-(0)71-524 8722  
[l.kruimer@crucell.com](mailto:l.kruimer@crucell.com)

### **DSM Biologics**

Marcel Lubben  
Business Manager Licensing  
Tel. + 31 (0)46 47 73343  
Fax. + 31 (0)46 47 73179  
[marcel-m.lubben@dsm.com](mailto:marcel-m.lubben@dsm.com)

### **For Crucell N.V. in the USA:**

Thomas Redington  
Tel. +1 212-926-1733  
[trredington@redingtoninc.com](mailto:trredington@redingtoninc.com)